Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Patients with histologically or cytologically confirmed locally advanced or
metastatic, non-resectable solid tumors whose disease has progressed despite standard
therapy or for whom no standard therapy exists

- Measurable disease as determined by RECIST 1.1

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Adequate hematological function

- Adequate liver function

- Adequate renal function

- Adequate coagulation

- Adequate cardiovascular function

- Recovery from all reversible adverse events of previous anti-cancer therapies to
baseline or CTCAE G 1, except for alopecia (any grade) and < or = G 2 sensory
peripheral neuropathy

Exclusion Criteria:

- Patients with primary CNS tumors or CNS tumor involvement. Patients with metastatic
CNS tumors may participate in this trial under conditions defined by protocol

- Patients with squamous non-small cell lung cancer histology

- Prior treatment with anti-angiogenic agents targeting VEGF/Ang-1/Ang-2/PIGF and its
receptors within 6 months prior to study drug administration

- Prior systemic anti-cancer therapy within the following timeframes: a) cyclical
chemotherapy within a period of time that is shorter than the cycle length for the
treatment used prior to study drug administration; b) biologic therapy or continuous
or intermittent treatment with small molecule therapeutics (targeted therapies)
within 4 weeks or < or = 5 half-lives of the drug concerned (whichever is shorter)
prior to study drug administration

- Treatment with any other investigational agents within less than the cycle length
used for that treatment or within 4 weeks (whichever is shorter) prior to study drug
administration

- Major surgery within 4 weeks prior to study drug administration

- Significant cardiovascular/cerebrovascular disease within 6 months prior to study
drug administration

- Known HIV infection or known active hepatitis B or hepatitis C virus infection

- Pregnant or nursing women